Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Clemens

Showing results (331-340 of 395) with videos related to

Pageof 40
Sort By:
Muscle & Nerve|May 17, 2013
The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods usedCraig M McDonald, Erik K Henricson, R Ted Abresch, et al.
British Journal of Cancer|November 2, 2016
Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trialsSteffen Ormanns, Michael Haas, Sibylle Baechmann, et al.
The Lancet. Neurology|December 1, 2009
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial managementKatharine Bushby, Richard Finkel, David J Birnkrant, et al.
Retina (Philadelphia, Pa.)|September 11, 2018
RANIBIZUMAB IN PIGMENT EPITHELIAL TEARS SECONDARY TO AGE-RELATED MACULAR DEGENERATION: A Prospective StudyPetra P Larsen, Akio Oishi, Mohammad Seleman Bedar, et al.
The Lancet. Neurology|December 1, 2009
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary careKatharine Bushby, Richard Finkel, David J Birnkrant, et al.
Muscle & Nerve|May 8, 2013
The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measuresErik K Henricson, R Ted Abresch, Avital Cnaan, et al.
Neurology|May 27, 2026
Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Comparison With Classic Corticosteroids From the FOR-DMD TrialPaula R Clemens, Anders Berglund, Marianela Schiava, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|August 7, 2009
Transforming growth factor-beta1 modulates insulin-like growth factor binding protein-4 expression and proteolysis in cultured periosteal explantsCarlos Gonzalez, Kiem G Auw Yang, Joseph H Schwab, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2002
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapyM D Green, H Koelbl, J Baselga, et al.
Annals of the Academy of Medicine, Singapore|May 1, 1997
Safety and efficacy of acellular pertussis vaccines: the Mainz study and other recent studiesJ A Weigl, H L Bock, R Clemens, et al.
Pageof 40

Showing results (331-340 of 395) with videos related to

Sort By:
Pageof 40
Muscle & Nerve|May 17, 2013
The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods usedCraig M McDonald, Erik K Henricson, R Ted Abresch, et al.
British Journal of Cancer|November 2, 2016
Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trialsSteffen Ormanns, Michael Haas, Sibylle Baechmann, et al.
The Lancet. Neurology|December 1, 2009
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial managementKatharine Bushby, Richard Finkel, David J Birnkrant, et al.
Retina (Philadelphia, Pa.)|September 11, 2018
RANIBIZUMAB IN PIGMENT EPITHELIAL TEARS SECONDARY TO AGE-RELATED MACULAR DEGENERATION: A Prospective StudyPetra P Larsen, Akio Oishi, Mohammad Seleman Bedar, et al.
The Lancet. Neurology|December 1, 2009
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary careKatharine Bushby, Richard Finkel, David J Birnkrant, et al.
Muscle & Nerve|May 8, 2013
The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measuresErik K Henricson, R Ted Abresch, Avital Cnaan, et al.
Neurology|May 27, 2026
Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Comparison With Classic Corticosteroids From the FOR-DMD TrialPaula R Clemens, Anders Berglund, Marianela Schiava, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|August 7, 2009
Transforming growth factor-beta1 modulates insulin-like growth factor binding protein-4 expression and proteolysis in cultured periosteal explantsCarlos Gonzalez, Kiem G Auw Yang, Joseph H Schwab, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2002
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapyM D Green, H Koelbl, J Baselga, et al.
Annals of the Academy of Medicine, Singapore|May 1, 1997
Safety and efficacy of acellular pertussis vaccines: the Mainz study and other recent studiesJ A Weigl, H L Bock, R Clemens, et al.
Pageof 40